Subjects

  • A Corrigendum to this article was published on 22 September 2004

Abstract

Arising from: R. L. Batterham et al. Nature 418, 650–654 (2002); Batterham et al. reply

Batterham et al. report that the gut peptide hormone PYY3–36 decreases food intake and body-weight gain in rodents1, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al.1 cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3–36.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature 418, 650–654 (2002).

  2. 2.

    et al. Pharmacol. Biochem. Behav. 61, 159–168 (1998).

  3. 3.

    et al. Endocrinology 141, 1011–1016 (2000).

  4. 4.

    et al. Digestion 30, 255–262 (1984).

  5. 5.

    Amersham Biosciences, RPNQ0085, Neuropeptide Y SPA binding assay (Y2).

  6. 6.

    et al. Endocrinology 145, 2585–2590 (2004).

  7. 7.

    et al. Biochem. Biophys. Res. Commun. 311, 915–919 (2003).

  8. 8.

    et al. Proc. Natl Acad. Sci. USA 101, 4695–4700 (2004).

  9. 9.

    et al. Gastroenterology 124, 1325–1336 (2003).

  10. 10.

    & Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R138–R142 (2004).

Download references

Author information

Affiliations

  1. Department of Psychiatry, University of Cincinnati Genome Research Institute, Cincinnati, Ohio 45237, USA

    • M. Tschöp
    • , T. R. Castañeda
    • , S. C. Benoit
    •  & R. J. Seeley
  2. German Institute of Human Nutrition, Potsdam-Rehbrücke 14558, Germany

    • M. Tschöp
    • , T. R. Castañeda
    • , H. G. Joost
    • , S. Ortmann
    •  & S. Klaus
  3. Center for Cardiovascular Research, Institute for Pharmacology and Toxicology, Charité University Hospital, Berlin 10115, Germany

    • C. Thöne-Reineke
  4. Institute for Zoo and Wildlife Research, Berlin 10315, Germany

    • S. Ortmann
  5. Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

    • M. M. Hagan
    • , P. C. Chandler
    •  & K. D. Oswald
  6. Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA

    • K. P. Kinzig
    •  & T. H. Moran
  7. Institute of Biochemistry, University of Leipzig, Leipzig 04103, Germany

    • A. G. Beck-Sickinger
    •  & N. Koglin
  8. Behavioural Pharmacology Laboratory, School of Psychology, University of Leeds, Leeds LS2 9JT, UK

    • R. J. Rodgers
    • , J. E. Blundell
    • , Y. Ishii
    • , A. H. Beattie
    •  & P. Holch
  9. Section on Statistical Genetics, Department of Biostatistics and Clinical Nutrition Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

    • D. B. Allison
  10. Novo Nordisk A/S, Discovery, Maaloev 2760, Denmark

    • K. Raun
    • , K. Madsen
    • , B. S. Wulff
    •  & C. E. Stidsen
  11. Peptides and Elephants GmbH, Potsdam-Rehbrücke 14558, Germany

    • M. Birringer
    •  & O. J. Kreuzer
  12. Boehringer-Ingelheim Pharma GmbH and Co. KG, Biberach 88397, Germany

    • M. Schindler
    • , K. Arndt
    • , K. Rudolf
    •  & M. Mark
  13. Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA

    • X. Y. Deng
    •  & D. C. Withcomb
  14. Biomeasure Incorporated/Ipsen Group, Milford, Massachusetts 01757, US

    • H. Halem
    • , J. Taylor
    • , J. Dong
    • , R. Datta
    •  & M. Culler
  15. Eli Lilly & Co. Research Laboratories, Indianapolis, Indiana 46285, USA

    • S. Craney
    • , D. Flora
    • , D. Smiley
    •  & M. L. Heiman

Authors

  1. Search for M. Tschöp in:

  2. Search for T. R. Castañeda in:

  3. Search for H. G. Joost in:

  4. Search for C. Thöne-Reineke in:

  5. Search for S. Ortmann in:

  6. Search for S. Klaus in:

  7. Search for M. M. Hagan in:

  8. Search for P. C. Chandler in:

  9. Search for K. D. Oswald in:

  10. Search for S. C. Benoit in:

  11. Search for R. J. Seeley in:

  12. Search for K. P. Kinzig in:

  13. Search for T. H. Moran in:

  14. Search for A. G. Beck-Sickinger in:

  15. Search for N. Koglin in:

  16. Search for R. J. Rodgers in:

  17. Search for J. E. Blundell in:

  18. Search for Y. Ishii in:

  19. Search for A. H. Beattie in:

  20. Search for P. Holch in:

  21. Search for D. B. Allison in:

  22. Search for K. Raun in:

  23. Search for K. Madsen in:

  24. Search for B. S. Wulff in:

  25. Search for C. E. Stidsen in:

  26. Search for M. Birringer in:

  27. Search for O. J. Kreuzer in:

  28. Search for M. Schindler in:

  29. Search for K. Arndt in:

  30. Search for K. Rudolf in:

  31. Search for M. Mark in:

  32. Search for X. Y. Deng in:

  33. Search for D. C. Withcomb in:

  34. Search for H. Halem in:

  35. Search for J. Taylor in:

  36. Search for J. Dong in:

  37. Search for R. Datta in:

  38. Search for M. Culler in:

  39. Search for S. Craney in:

  40. Search for D. Flora in:

  41. Search for D. Smiley in:

  42. Search for M. L. Heiman in:

Competing interests

Several of the authors consult with, and have received financial support from, companies and institutions, including pharmaceutical firms, that may have active programmes relating to PYY3–36 of which we are not aware. Several of these companies have obesity-treatment development programmes and may therefore, from some perspectives, be considered competitors to companies pursuing PYY3–36.

Corresponding author

Correspondence to M. Tschöp.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature02665

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.